Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981837 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01981837 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT01981837, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.
Interventions
- DRUG ALN-TTRSC (revusiran) for subcutaneous administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981837
The ClinicalTrials.gov registry entry for NCT01981837 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALN-TTRSC (revusiran) for subcutaneous administration is the first listed.
NCT01981837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981837 about?
NCT01981837 is a clinical study titled "Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis". The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.
What is the current status of trial NCT01981837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2013-12. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01981837?
The interventions under investigation include: ALN-TTRSC (revusiran) for subcutaneous administration (DRUG).
Who is sponsoring clinical trial NCT01981837?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.